#91

Believe what you wish to believe. If you don’t need supporting evidence, go for it. It’s your life. You can trust whatever sources you choose. I will go with trusted sources and well documented evidence.

1 Like
#92

It’s strange that Essex Bio-Technology Ltd secured all the rights, including the right to sell, and the drops are still available only in Russia. Was the stage 3 FDA approved trial completed by Essex? If not, could it be that what is sold by Russian pharmacies now is not authentic? Or could it be that they are selling what was produced prior to acquisition?

image
image1284×2778 167 KB

2 Likes
#93

In my view, I have been using Visomitin (SKQ1) eyedrops since 2017 on and off. I have enough “supporting information” to satisfy my decision and that was information from over 5 years ago.

The API* is available on the market just as any other API.

This discussion has rekindled my interest in an IV solution, enough to get copies of both Skulachev published books.

*active pharmaceutical ingredient

1 Like
#94

Do you observe any positive/negative results?

#95

Can not say either way.
I am not the “going to see a doctor” type.

Was told{had to have an eye exam for a required document] I was developing “slight cataracts on the edges” back in 2012 - 2013, looking for my own solution to this, came access the video aired back in 2013. Tracked down the eyedrops and purchased.

1 Like
#96

The three Mitotech official company web site’s I am aware of.

Two Russian sites are;

And

The English site;

#97

This is where I got the 50% of Russian papers are fake data from (It’s actually 48.3% - the highest of any country)

https://spotify.localizer.co/uploads/default/original/2X/d/d74c11dda199e8a1ba78310d53a38983afa81d4e.png

1 Like
#98

Have you read the paper itself?
I believe it quite questionable (especially criteria for flagging a paper potentially fake) and the paper hasn’t been peer reviewed yet, it is a preprint.
And Russian potentially fake papers represent only over 2% global fake papers in this study. And most (if not all) of the papers posted above on SkQ1 were peer reviewed and printed in western publications so the potential of being fake would be really measured in few percents.

3 Likes
#99

I just wanted to bring attention to the source of where it said about 50% of Chinese and Russian (and Turkish) papers are fake. SKQ1 may be in the good 50%. I just need more proof before I act on anything from countries with such a high fake percentage.

#100

They have a US patent.

Patent page also shows active patents in Canada, Australia, Japan, Spain, among others.

Worldwide applications

2012 US EP EA JP CN ES AU BR CA WO 2015 US 2017 JP

#101

That’s the bottom line… I like how @RapAdmin is thinking, we should just focus on the science, let’s ignore where papers are from.

#102

You thought they would not?

And if you have reviewed the patent, you would see formulations covering IV and other injection methods…

#103

Just sharing what I saw. I am not an oppositor here.

Considering that they have a patent, here, can’t see why it is not made available here.

#104

The compound{SkQ} is available, as product’s and the API*

*active pharmaceutical ingredient

#105

I found this topic after listening to a Sandra Kaufmann interview where she mentioned a product called Visomitin (SkQ1). Reading through this long topic and some of the publications mentioned by others I did a little bit of research looking for studies done in the USA. I found two studies that have apparently been completed, but without any results being posted. Well, when results aren’t posted I wonder if it’s because they were negative. These particular studies were sponsored by Mitotech, SA, which seems to be following up on the work done at Moscow State University under the direction of former Professor Vladimir Skulachev. Mitotech, SA (Luxembourg-based biotechnology company) produces SkQ1.

So, does SkQ1 actually work or not? Well, it would be great if it did, but I’m still skeptical. For those who have used it, did you notice any improvement? You may have reported this before, but this is a long topic and if you did, I missed it.

The reading in the trials noted below is brief. If you read them and find any posted results, I would like to know about it.

https://clinicaltrials.gov/study/NCT03764735

https://clinicaltrials.gov/study/NCT04206020

#106

Skimming this thread I haven’t seen mention that MitoQ (a related agent) failed its ITP run. SkQ1 is claimed to be a better option, but IMO MitoQ should be good enough to test the proposed mechanism. So my prediction is that a similar test of SkQ1 would show a very small effect, if any.

1 Like
#107

I’m about to take the plunge. I’ve found a source that seems okay (I think)

My question is: is this taken orally and if so, does that get through the digestive tract into the whole body?

#108

I have been using Visomitin eye drops (with SkQ1) for 1 month. Plan to continue for 1 year (until supplies last). Do not know what results to expect or how to test the outcomes.

1 Like
#109

Have you noticed any benefits for your vision?

#110

No changes. I do not have any problems though with my vision. I am taking it preventively. Because of that it could be difficult to see any benefit.

2 Likes